Tag: drug-coated balloons
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for...
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease received treatment with paclitaxel-coated (drug-coated balloons or...
Paclitaxel situation “crystallising” thanks to new data and teamwork, VIVA audience...
This year's Vascular Interventional Advances annual meeting (VIVA 2020; 6–8 November, online) opened with a session on controversial hot topics and advanced multidisciplinary approaches...
VIVA 2019: SELUTION sirolimus DCB safe and effective through two years
The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...
Philips receives FDA approval for low-dose drug-coated balloons
Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of...
A panel of experts comments on IN.PACT AV ACCESS data
NOTE: This video is ONLY available to watch in selected countries and geographies
Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...
MHRA issues medical device alert for paclitaxel use in the UK
Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
Meta-analysis finds a higher risk of death in the long term...
New data, just published in the Journal of the American Heart Association (JAHA), suggest that there is an increased risk of death at two...
Without additional long-term and patient-level data, Katsanos et al’s conclusion is...
By Thomas Zeller
The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...